Karolinska Development's portfolio company Modus Theraputics has secured two new US-based patents for its drug sevuparin.
The two patents have been granted claims for the substance sevuparin per se and a manufacturing method for producing sevuparin, as well as its use in sickle-cell disease (SCD).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The patents granted by the United States Patent and Trademark Office (USPTO) will enable key intellectual property protection in the US for sevuparin until at least December 2032.
Modus Therapeutics is currently enrolling SCD patients into a multi-centre, international, randomised Phase II study in Europe and the Middle East.
This proof-of-concept study is intended to show reduced time to resolution of Vaso-Occlusive Crises (VOC) in SCD patients.
Modus Therapeutics CEO Christina Herder said: “The grant of these two US patents is a major milestone for Modus Therapeutics as they provide important IP protection for sevuparin and its use for SCD.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"The US has an estimated 100,000 SCD patients, and therefore represents a significant opportunity for sevuparin.”
Karolinska Development chief investment officer Viktor Drvota said: “This is a positive development for Modus Therapeutics, providing a strong foundation for the development and future commercialisation of sevuparin in the US.”
